AstraZeneca (AZN) News Today → [URGENT] DO NOT Touch These AI Stocks! (From Weiss Ratings) (Ad) Free AZN Stock Alerts £121.10 -56.00 (-0.46%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 12:29 PM | benzinga.comAstraZeneca's COVID-19 Prevention Therapy Cuts Risk Of Infection In Patients With Weaker Immunity, Data ShowsMay 16 at 12:29 PM | msn.comAstraZeneca COVID therapy succeeds in late-stage study for the vulnerableMay 15, 2024 | americanbankingnews.comAstraZeneca (LON:AZN) Share Price Passes Above 200-Day Moving Average of $10,561.77May 15, 2024 | marketbeat.comAstraZeneca (LON:AZN) Stock Crosses Above Two Hundred Day Moving Average of $10,561.77AstraZeneca (LON:AZN) Shares Cross Above 200-Day Moving Average of $10,561.77May 9, 2024 | msn.comAstraZenca is pulling its COVID-19 vaccineMay 8, 2024 | marketwatch.comAstraZeneca pulls its COVID-19 vaccine from the European marketMay 7, 2024 | msn.comAstraZeneca says it will withdraw COVID-19 vaccine globally as demand dipsMay 7, 2024 | marketbeat.comAstraZeneca (LON:AZN) PT Raised to £130 at Berenberg BankBerenberg Bank raised their price target on shares of AstraZeneca from £120 ($150.75) to £130 ($163.32) and gave the company a "buy" rating in a report on Friday.May 2, 2024 | markets.businessinsider.comAstraZeneca: Strong Q1 Earnings and Promising Pipeline Reinforce Buy RatingApril 30, 2024 | msn.comNovo, Teva, AstraZeneca issued FTC warnings over ‘bogus’ patentsApril 29, 2024 | markets.businessinsider.comAstraZeneca: Enhertu Improved PFS In HR-positive, HER2-low Metastatic Breast CancerApril 27, 2024 | finance.yahoo.comAstraZeneca PLC (LON:AZN) Beat Earnings, And Analysts Have Been Reviewing Their ForecastsApril 25, 2024 | markets.businessinsider.comAstraZeneca Q1 Profit, Revenues Climb; Backs FY24 OutlookApril 20, 2024 | msn.comBrexit Impact On Drugs - Rising Shortages in UK Highlight Brexit ChallengesApril 18, 2024 | uk.finance.yahoo.comI don’t care how much FTSE bosses are paid as long as they make me rich!April 17, 2024 | marketbeat.comAstraZeneca (LON:AZN) Upgraded at Deutsche Bank AktiengesellschaftDeutsche Bank Aktiengesellschaft upgraded AstraZeneca to a "hold" rating in a research report on Monday.April 15, 2024 | marketbeat.comAstraZeneca (LON:AZN) Rating Reiterated by Shore CapitalShore Capital restated a "buy" rating on shares of AstraZeneca in a research note on Monday.April 11, 2024 | msn.comUK Stocks: AstraZeneca (AZN) Assures Dividend Growth Before CEO Pay VoteApril 11, 2024 | uk.investing.comLok’nStore, AstraZeneca, Darktrace, Distil, European Metals, XPS Pensions, Mast Energy – Stocks on the moveApril 11, 2024 | finance.yahoo.comTrending tickers: Darktrace, AstraZeneca, Persimmon, BitcoinApril 11, 2024 | marketwatch.comAstraZeneca: Board to Raise Annualised Div by $0.20 to $3.10 Per ShrApril 9, 2024 | marketbeat.comAstraZeneca (LON:AZN) Reaches New 1-Year Low at $105.92AstraZeneca (LON:AZN) Reaches New 12-Month Low at $105.92April 8, 2024 | marketbeat.comAstraZeneca (LON:AZN) Receives "Overweight" Rating from BarclaysBarclays reaffirmed an "overweight" rating and issued a £125 ($156.92) price objective on shares of AstraZeneca in a research note on Monday.April 8, 2024 | msn.comAstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid TumorApril 5, 2024 | marketbeat.comShore Capital Reaffirms "Buy" Rating for AstraZeneca (LON:AZN)Shore Capital reaffirmed a "buy" rating on shares of AstraZeneca in a research report on Friday.April 5, 2024 | msn.comPharma Stock Roundup: AZN Voydeya Gets FDA Nod, MRK KRAS Inhibitor Enters Phase IIIApril 4, 2024 | marketbeat.comAstraZeneca (LON:AZN) Given "Overweight" Rating at JPMorgan Chase & Co.JPMorgan Chase & Co. reiterated an "overweight" rating on shares of AstraZeneca in a research note on Thursday.April 3, 2024 | benzinga.comA Closer Look at AstraZeneca's Options Market DynamicsMarch 27, 2024 | msn.comJapan approves AstraZeneca-Sanofi drug for prevention of RSV disease in infantsMarch 19, 2024 | msn.comAstraZeneca bets on new cancer treatments with $2 billion Fusion Pharma purchaseMarch 19, 2024 | nasdaq.comAstraZeneca To Buy Fusion Pharma For Up To $2.4 BlnMarch 16, 2024 | finance.yahoo.comAZN Apr 2024 72.000 callMarch 14, 2024 | finance.yahoo.comAZN May 2024 67.500 callMarch 12, 2024 | marketbeat.comAstraZeneca's (AZN) "Sell" Rating Reiterated at Deutsche Bank AktiengesellschaftDeutsche Bank Aktiengesellschaft reiterated a "sell" rating on shares of AstraZeneca in a report on Tuesday.March 11, 2024 | marketbeat.comAstraZeneca PLC (LON:AZN) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesAstraZeneca PLC (LON:AZN - Get Free Report) has been given an average rating of "Moderate Buy" by the ten brokerages that are presently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and seven have issuedMarch 5, 2024 | finance.yahoo.comAZN Apr 2024 60.000 putFebruary 27, 2024 | marketbeat.comDeutsche Bank Aktiengesellschaft Reaffirms Sell Rating for AstraZeneca (LON:AZN)Deutsche Bank Aktiengesellschaft restated a "sell" rating and set a GBX 9,500 ($120.50) target price on shares of AstraZeneca in a report on Tuesday.February 25, 2024 | finance.yahoo.comAZN Apr 2024 67.000 callFebruary 23, 2024 | finance.yahoo.comAZN Mar 2024 57.000 callFebruary 23, 2024 | finance.yahoo.comAZN Mar 2024 68.000 putFebruary 22, 2024 | benzinga.comAstraZeneca Stock (NASDAQ:AZN) Insider TradesFebruary 22, 2024 | markets.businessinsider.comAstraZeneca Prices $5bln Four Tranche Notes OfferingFebruary 20, 2024 | msn.comGracell Biotechnologies receives shareholder approval for merger with AstraZenecaFebruary 20, 2024 | marketbeat.comAstraZeneca (LON:AZN) Price Target Cut to GBX 120Berenberg Bank reduced their price objective on shares of AstraZeneca from GBX 125 ($1.57) to GBX 120 ($1.51) and set a "buy" rating on the stock in a research note on Monday.February 19, 2024 | finance.yahoo.comAZN Oct 2024 62.500 putFebruary 19, 2024 | markets.businessinsider.comAstraZeneca's Tagrisso With Chemotherapy Approved In US To Treat Lung CancerFebruary 19, 2024 | msn.comUK shares muted on receding rate cut bets; AstraZeneca gainsFebruary 17, 2024 | finance.yahoo.comAZN Feb 2024 69.000 callFebruary 16, 2024 | marketbeat.comAstraZeneca (LON:AZN) Rating Reiterated by Jefferies Financial GroupJefferies Financial Group reissued a "hold" rating and issued a £110 ($138.92) price target on shares of AstraZeneca in a report on Friday.February 15, 2024 | marketbeat.comAstraZeneca PLC (LON:AZN) Given Consensus Rating of "Moderate Buy" by BrokeragesAstraZeneca PLC (LON:AZN - Get Free Report) has received an average recommendation of "Moderate Buy" from the ten brokerages that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a Get AstraZeneca News Delivered to You Automatically Sign up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter. Email Address The ONE AI Stock to own now. (It’s not Nvidia.) (Ad)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made … Click here to see the presentation now. AZN Media Mentions By Week AZN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AZN News Sentiment▼0.200.43▲Average Medical News Sentiment AZN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AZN Articles This Week▼42▲AZN Articles Average Week Get AstraZeneca News Delivered to You Automatically Sign up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: GSK News Dechra Pharmaceuticals News Haleon News Smith & Nephew News ConvaTec Group News Hikma Pharmaceuticals News HUTCHMED News Indivior News EMIS Group News Genus News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:AZN) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders41 banks launch ‘crypto dollar’Stansberry ResearchClaim Your Complimentary Bitcoin RewardCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AstraZeneca PLC Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
